Cargando…

Pharmacology and Emerging Therapies for Group 3 Pulmonary Hypertension Due to Chronic Lung Disease

Pulmonary hypertension (PH) frequently complicates chronic lung disease and is associated with high morbidity and poor outcomes. Individuals with interstitial lung disease and chronic obstructive pulmonary disease develop PH due to structural changes associated with the destruction of lung parenchym...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gonzales, Janae, Fraidenburg, Dustin R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058846/ https://www.ncbi.nlm.nih.gov/pubmed/36986517 http://dx.doi.org/10.3390/ph16030418

Ejemplares similares

Caught in a vicious cycle: Cell‐free hemoglobin and the pathogenesis of pulmonary hypertension
por: Gonzales, Janae, et al.
Publicado: (2023)

Hemin-Induced Endothelial Dysfunction and Endothelial to Mesenchymal Transition in the Pathogenesis of Pulmonary Hypertension Due to Chronic Hemolysis
por: Gonzales, Janae, et al.
Publicado: (2022)

Non-Muscle MLCK Contributes to Endothelial Cell Hyper-Proliferation through the ERK Pathway as a Mechanism for Vascular Remodeling in Pulmonary Hypertension
por: Anis, Mariam, et al.
Publicado: (2022)

Bosentan as Rescue Treatment in Refractory Hypoxemia and Pulmonary Hypertension in a Patient with ARDS and H7N9 Influenza Virus Infection
por: Guo, Qiang, et al.
Publicado: (2014)

Management of Pulmonary Hypertension Due to Chronic Lung Disease
por: Sugarman, Jordan, et al.
Publicado: (2021)

Pulmonary hypertension in chronic lung diseases: comparison to other pulmonary hypertension groups
por: Chebib, Nader, et al.
Publicado: (2018)

Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension
por: Hoeper, Marius M.
Publicado: (2015)

Thrombin‐mediated activation of Akt signaling contributes to pulmonary vascular remodeling in pulmonary hypertension
por: Ogawa, Aiko, et al.
Publicado: (2013)

The Challenge to Decide between Pulmonary Hypertension Due to Chronic Lung Disease and PAH with Chronic Lung Disease
por: Olschewski, Horst
Publicado: (2021)

Impact of targeted pulmonary arterial hypertension therapies in severe pulmonary hypertension in chronic lung diseases
por: Naud, Romain, et al.
Publicado: (2023)

Pathogenic Mechanisms of Pulmonary Arterial Hypertension: Homeostasis Imbalance of Endothelium-Derived Relaxing and Contracting Factors
por: Zhu, Jinsheng, et al.
Publicado: (2022)

Adherence to pharmacological therapy for hypertension: Focus group with patients
por: Rosendo-Silva, Beatriz, et al.
Publicado: (2023)

Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary hypertension due to lung diseases and/or hypoxia
por: Sakkijha, Husam, et al.
Publicado: (2014)

Expression profile of mitochondrial voltage-dependent anion channel-1 (VDAC1) influenced genes is associated with pulmonary hypertension
por: Zhou, Tong, et al.
Publicado: (2017)

Pulmonary hypertension in chronic lung disease and hypoxia
por: Nathan, Steven D., et al.
Publicado: (2019)

Survival in severe pulmonary hypertension due to chronic lung disease: influence of in-hospital platelet distribution width
por: Wang, Lan, et al.
Publicado: (2021)

Pharmacological therapy for stable chronic obstructive pulmonary disease
por: Duan, Ruirui, et al.
Publicado: (2023)

Chronic obstructive pulmonary disease phenotypes: imprint on pharmacological and non-pharmacological therapy
por: Bakeer, Mostafa, et al.
Publicado: (2020)

Pulmonary arterial hypertension due to antiphospholipid syndrome initially mimicking chronic thromboembolic pulmonary hypertension
por: Yeo, Jina, et al.
Publicado: (2022)

Beyond the Diagnosis of Group IV Pulmonary Hypertension: Chronic Thromboembolic Pulmonary Hypertension Mimickers
por: Chima, Noor Rehman, et al.
Publicado: (2020)

Upregulated Copper Transporters in Hypoxia-Induced Pulmonary Hypertension
por: Zimnicka, Adriana M., et al.
Publicado: (2014)

Efficacy of Dabigatran in Pulmonary Embolism Due to Thrombophilia in Chronic Thromboembolic Pulmonary Hypertension
por: Muscoli, Saverio
Publicado: (2020)

Chronic Thromboembolic Pulmonary Hypertension Due to Popliteal Vein Aneurysm
por: Tsubono, Masakazu, et al.
Publicado: (2021)

Emerging Metabolic Therapies in Pulmonary Arterial Hypertension
por: Harvey, Lloyd D., et al.
Publicado: (2017)

Pulmonary hypertension due to interstitial lung disease or chronic obstructive pulmonary disease: a patient experience study of symptoms and their impact on quality of life
por: DuBrock, Hilary M., et al.
Publicado: (2021)

Lung Cavities in Chronic Thromboembolic Pulmonary Hypertension
por: Fernandes, Caio Julio Cesar dos Santos, et al.
Publicado: (2020)

Group 3 pulmonary hypertension: Challenges and opportunities
por: McGettrick, Michael, et al.
Publicado: (2020)

Pulmonary Hypertension and Right Heart Dysfunction in Chronic Lung Disease
por: Zangiabadi, Amirmasoud, et al.
Publicado: (2014)

Allopurinol in Patients with Pulmonary Hypertension Associated with Chronic Lung Disease
por: Liu-Shiu-Cheong, Patrick S K, et al.
Publicado: (2020)

Atrial arrhythmias in chronic lung disease-associated pulmonary hypertension
por: Vahdatpour, Cyrus A., et al.
Publicado: (2020)

The Effect of Borderline Pulmonary Hypertension on Survival in Chronic Lung Disease
por: Piccari, Lucilla, et al.
Publicado: (2022)

Pulmonary hypertension and chronic lung disease: where are we headed?
por: Elia, Davide, et al.
Publicado: (2019)

Macrolides: a promising pharmacologic therapy for chronic obstructive pulmonary disease
por: Qiu, Shilin, et al.
Publicado: (2016)

MicroRNA-212-5p, an anti-proliferative miRNA, attenuates hypoxia and sugen/hypoxia-induced pulmonary hypertension in rodents
por: Chen, Tianji, et al.
Publicado: (2022)

Pulmonary hypertension due to left heart disease
por: Vachiéry, Jean-Luc, et al.
Publicado: (2019)

Pulmonary hypertension due to unclassified interstitial lung disease in a Pembroke Welsh corgi
por: MORITA, Tomoya, et al.
Publicado: (2018)

Pulmonary Hypertension due to Lung Diseases and/or Hypoxia: What Do We Actually Know?
por: Kosanovic, Djuro, et al.
Publicado: (2017)

Giant Pulmonary Artery Thrombotic Material, Due to Chronic Thromboembolic Pulmonary Hypertension, Mimics Pulmonary Artery Sarcoma
por: Triantafyllidi, Helen, et al.
Publicado: (2021)

Retrospective evaluation of pimobendan and sildenafil therapy for severe pulmonary hypertension due to lung disease and hypoxia in 28 dogs (2007–2013)
por: Murphy, Lisa A., et al.
Publicado: (2017)

Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary hypertension due to left heart disease
por: Alhabeeb, Waleed, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_uoeeb802eo3e4asvdn7fi3pjfd